Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
Acknowledgment: This story is sponsored by Takeda and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing relevant, vetted and valuable information to the…
NLS Pharma has just announced new data which further supports the mechanism of action of Mazindol. Mazindol is the active ingredient in Quilience, a treatment used for narcolepsy. This therapy…
Suddenly Sleepy Saturday, a day dedicated to spreading awareness about narcolepsy, is being held on March 13, 2021. The Narcolepsy Network is looking for volunteers to send a proclamation request…
Have you ever had a feeling that you knew something was off, but you just didn't know what? That is how I felt for more than half of my life.…
The SLEEP 2020 Annual Meeting will be held virtually due to the COVID-19 pandemic, but that is not stopping Axsome Therapeutics from presenting the results of their Phase 2 CONCERT…
The 34th Annual Meeting of the Associated Professional Sleep Societies, or "SLEEP 2020," was held last week from August 27th through the 30th. According to BioSpace, pharmaceutical company Harmony Biosciences…
According to a story from Medscape, the US Food and Drug Administration (FDA) has recently approved a new oral solution as a treatment for symptoms associated with narcolepsy, a rare…
According to a story from Sleep Review, the drug company Jazz Pharmaceuticals plc has recently filed a New Drug Application (NDA) for its investigational treatment JZP-258, which is being developed…
This is part two of the story, click here to read part one After searching for a new neurologist, we found one only 30 mins away that was willing…
I want to start off by saying that the intention behind my words are not to convey or express any sort of anger, hatred, or resentment. I am choosing to…
According to a story from Biotech 365, the biopharmaceutical company Avadel Pharmaceuticals plc recently announced that it has completed enrollment for its phase 3 clinical trial. This trial will test…
Narcolepsy is characterized by drowsiness, often during the daytime. This is a symptom that greatly affects the lives of those with narcolepsy, and for a long time no FDA…
Narcolepsy is a rare neurological disease that affects the sleep cycle. Symptoms include sleep paralysis, excessive daytime sleepiness, disrupted nighttime sleep, hypnagogic hallucinations, and, for around 70% of patients, cataplexy.…
According to a story from PR Newswire, the biopharmaceutical company Harmony Biosciences, LLC recently announced that the US Food and Drug Administration (FDA) has approved the company's drug pitolisant (marketed…
The State of Rare Diseases in China The Illness Challenge Foundation (ICF) is an organization devoted to easing the burdens that rare disease patients living in China face. They accomplish this…
According to a story from Neuroscience News, a team of researchers based out of the University of Copenhagen have made an intriguing discovery that could give new insight into the…
According to a story from finanznachrichten.de, the biopharmaceutical company Theranexus has recently released preliminary results from a Phase II clinical trial that is testing the company's experimental product THN102. This…
Emmanuel Mignot, who is the director of the Stanford Center for Sleep Sciences and Medicine has long believed that some onsets of Narcolepsy could be caused by a confused autoimmune response in…
Narcolepsy and Cataplexy Narcolepsy is a neurological condition that results in a malfunctioning sleep-wake cycle. It affects approximately 185,000 individuals in the United States alone. Some of the most common…
A study has found that daytime sleepiness and attention may be correlated in people with narcolepsy and hypersomnia, with patients who self-report feeling more sleepy also being more likely to…
The FDA has approved a new narcolepsy and cataplexy treatment for pediatric patients! Xyrem is a drug used to control narcolepsy symptoms including cataplexy and excessive daytime sleepiness (EDS). It…
The United States Food and Drug Administration has awarded Orphan Drug Designation to an investigational drug for narcolepsy, and there are plans to carry out a Phase 2 study to…
A new study explored the mechanisms underlying narcolepsy, a rare sleep disorder. The condition has previously been linked to reduced levels of a neurotransmitter called hypocretin, and the recent study…
According to a story from kait8.com, the company Harmony Biosciences, Inc., has recently announced that the U.S. FDA has given Fast Track and Breakthrough Therapy designations for its experimental therapy…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
